Abstract
Myocardial infarction (MI) is a deadly disease that threatens global health. During pathogenesis, excessive oxidative stress and inflammatory responses may accelerate disease progression and cardiac dysfunction. However, the treatment with naturally active and gene-based drugs is limited by the complex microenvironment within the lesions. Therefore, this study aimed to construct a nanosystem co-delivering Dioscin (Dio) and small interfering RNA (siRNA) of intercellular adhesion molecule-1 (siICAM-1) to repair cardiac function after MI. Nanomaterials were also equipped with polydopamine (PDA) and CD11b to respond to reactive oxygen species/pH in the lesion environment and target neutrophils, respectively. As expected, Dio/siICAM-1@MSN@PDA-CD11b was successfully constructed to realize the rapid release of Dio and siICAM-1 under condition of pH6.4+H2O2. It also exhibited enhanced targeting properties with more intracellular uptake by neutrophils. In vitro, after co-culture with nanoparticle-targeted neutrophil, damaged cardiomyocytes regained their proliferative capacity, accompanied by a decrease in the level of inflammatory cytokines and the repair of mitochondrial dysfunction. Pharmacokinetic evaluation revealed that Dio/siICAM-1@MSN@PDA-CD11b exhibited a markedly prolonged plasma clearance and extended blood circulation half-time. In vivo, Dio/siICAM-1@MSN@PDA-CD11b preferentially accumulated within the myocardial tissues of MI mice and co-localized with CD11b+Ly6G+ neutrophils, thereby attenuating neutrophil recruitment, suppressing inflammatory responses, and ultimately improving cardiac function. More importantly, Dio/siICAM-1@MSN@PDA-CD11b exhibited excellent in vivo biosafety profiles. To conclude, Dio/siICAM-1@MSN@PDA-CD11b demonstrated the potential to improve cardiac function after MI by blocking neutrophil infiltration into damaged cardiomyocytes to alleviate the inflammatory response and avoid further disease progression. This co-delivery nanosystem therefore proposed a spatiotemporal paradigm for the treatment of MI, with prospects for clinical transformation.
Keywords: Myocardial infarction, Nano co-delivery system, ROS/pH-response, Dioscin, ICAM-1, Inflammation response, Cardiac repair
Graphical abstract
Highlights
-
•
Dio/siICAM-1@MSN@PDA-CD11b is pH/ROS dual-responsive and neutrophil-targeted.
-
•
Nanosystem co-delivering Dio and siICAM-1 improves cardiac repair after MI by blocking neutrophil recruitment.
-
•
Dio/siICAM-1@MSN@PDA-CD11b reduces inflammation and mitochondrial dysfunction in damaged cardiomyocytes.
1. Introduction
Myocardial infarction (MI) is a fatal coronary-associated pathology triggered by hypoxia of cardiomyocytes and ischemic necrosis caused by reduced blood flow [1,2]. It leads to a series of cardiac pathologies including ischemia/reperfusion injury, inflammation, fibrosis, ventricular remodeling, and ultimately heart failure [3]. The average age of patients with MI has dropped from 71 to 68 years, which has now become a major global health threat [4]. In MI, neutrophils exert effects on myocardial ischemia, reperfusion injury, and heart failure after MI that extend beyond their traditional immune functions [5]. At the onset of disease, neutrophils rapidly infiltrate the infarcted myocardium, producing large quantities of reactive oxygen species (ROS) and amplifying the inflammatory response [6]. It was reported that degranulation of activated neutrophils and subsequent release of granular proteins contribute to MI pathogenesis [7]. Notably, therapeutic blockade of CD11b has been shown to attenuate myocardial ischemia/reperfusion injury by reducing neutrophil infiltration [8]. As the early responders to MI, neutrophils are therefore considered key therapeutic targets.
Dioscin (Dio), a natural and biologically active steroidal saponin, has positive effects on multiple organ damage [9]. Kong et al. [10] demonstrated that Dio significantly improved endothelial cell angiogenic activity in MI mice while reducing myocardial fibrosis and apoptosis. Meanwhile, Dio exerts its anti-MI effect by regulating BMP4/NOX1-mediated oxidative stress and inflammation [11]. Chinese medicinal preparations with Dio as the main ingredient have been found to have pharmacological effects, such as vasodilating, reducing blood pressure and cardiac load, improving hemodynamics, and antiplatelet aggregation, and therefore been used in the treatment of MI [12]. More importantly, Dio can reduce the inflammatory lesions and neutrophil motility in animal-based experiments [13,14]. In addition to natural drugs, gene drugs are also gradually being popularized in the treatment of MI. Among them, intercellular adhesion molecule-1 (ICAM-1), which mediates neutrophil migration to endothelial cells at sites of chronic inflammation, might be a potential therapeutic target for MI [15,16]. Relevant studies concluded that ICAM-1 is closely related to the pathogenesis of coronary artery disease and MI, especially its genetic polymorphisms on G241R, K469E and rs5498 [[17], [18], [19]]. Furthermore, ICAM-1 can be used as a potent biomarker to predict the risk of heart failure after MI [20]. Previous studies have demonstrated that a subset of neutrophils expressing ICAM-1 can produce high levels of ROS, thereby influencing inflammatory responses [21]. Mechanistically, ICAM-1 interaction with surface receptors may regulate neutrophil trafficking during inflammatory processes [22]. However, the therapeutic efficacy of these natural and genetic drugs is limited by their chemical and physical instability, poor bioavailability, drug resistance, and cytotoxicity, which has given rise to the application of nanomaterials for targeted delivery of drugs.
Mesoporous silica nanoparticle (MSN) has become one of the most widely used nanomaterials in recent years due to its good biocompatibility, large specific surface area for drug loading, ease of modification, stability, and simplicity of preparation [23,24]. These properties enable it to efficiently load therapeutic drugs, including small molecules, genes, peptides, and proteins, via electrostatic adsorption or chemical bonding, thus ultimately realizing targeted delivery and therapy [[25], [26], [27]]. On the other hand, it can be used as a substrate material for modifying “gatekeepers” with different stimulation responses on the surface to achieve the controlled release of drugs [28,29]. Considering that the occurrence of MI is accompanied by the production of a large number of ROS and a decrease in pH, polydopamine (PDA) may be a suitable “gatekeeper”. PDA is a mussel-inspired biomaterial with strong adhesion ability and is sensitive to ROS and pH [30]. PDA is formed by the aggregation of dopamine under alkaline conditions by covalent and non-covalent bonds, with the property of responding to and clearing ROS [31]. A system for the treatment of MI has been proposed by encapsulating PDA to achieve dual response to ROS and pH and delivering drug-loaded nanomaterials [32].
We are therefore inspired that co-delivery of Dio and small interfering RNA (siRNA) of ICAM-1 (siICAM-1) could be achieved by synthesizing MSN nanomaterials. To better target the lesion, we encapsulated ROS/pH dual-responsive PDA and gave antibody labeling for CD11b to recognize neutrophils. The main objective of this nano-delivery system is to block the recruitment of neutrophils to damaged cardiomyocytes upon MI onset, thereby scavenging ROS, suppressing inflammation, and ultimately improving cardiomyocyte repair (Fig. 1). Based on the successful construction of the co-delivery system, this study also performed in vitro and in vivo experiments to evaluate its targeting and cardiac repair capacity, while observing its effects on inflammatory response and mitochondrial function. We expect that this drug delivery system can be applied to the clinical treatment of MI and improve the overall therapeutic efficacy.
Fig. 1.
Schematic summary of the ROS-responsive nanoparticles for blocking neutrophil recruitment and anti-inflammatory treatment against MI injury.
2. Materials and methods
2.1. Materials
Hexadecyl trimethyl ammonium chloride (CTAC, S15002), tetraethyl orthosilicate (TEOS, W10265), and lipopolysaccharides (LPS, S11060) were provided by Shanghai Yuanye Bio-Technology Co., Ltd. Trolamine Triethanolamine (TEA, 190062), polydopamine (PDA, D9520), Dio (SD8350), dimethyl sulfoxide (DMSO, D8371), and Mayer's hematoxylin stain (G1080) were purchased from Beijing Solarbio Science & Technology Co.,Ltd. Ethyl alcohol (10009218) and H2O2 (10011208) were obtained from the China National Pharmaceutical Group Co Ltd (Sinopharm). Tris-HCl (ST768), fluorescein isothiocyanate (FITC, ST2065), 4′,6-diamidino-2-phenylindole (DAPI, C1005), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, ST1299), and antifade mounting medium (P0126) were supplied by Shanghai Beyotime Biotechnology. The anti-CD11b (ab52478), anti-ICAM-1 (ab282575), anti-TNF-α (ab215188), anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, ab181602), anti-CD11b (ab133357), anti-Ly6G (ab238132), goat anti-rabbit IgG H&L (Alexa Fluor® 647, ab150079), and goat anti-mouse lgG H&L (Alexa Fluor® 594, ab150116) antibodies were purchased from Abcam. The anti-NF-κB (AF2006), anti-STAT3 (AF6294), anti-p-STAT3 (AF3293), and anti-p-38 (AF4001) antibodies were obtained from Affinity Biosciences LTD. The anti-p38 (#8690) and anti-p-NF-κB (#3033) antibodies were provided by Cell Signaling Technology. The mouse CD11b-FITC conjugated antibody (bsm-30306A-FITC) and mouse Gr-1/Ly-6G PE-conjugated antibody (FAB1037P) were purchased from Bioss and R&D Systems, respectively. Sequences of small interfering RNA (siRNA) of ICAM-1 (siICAM-1) were designed in the website of Designer of Small Interfering RNA as following: SS-UUGAAUAGCACAUUGGUUGGC, AS-UUGAAUAGCACAUUGGUUGGC.
2.2. Preparation of nanoparticles
MSN: To synthesis MSN, a mixture of 2 g CTAC, 0.1 g TEA, and 20 mL of deionized water was first prepared. Over the next 20–30 min, 1.5 mL of TEOS was added to the mixture while stirring. After centrifugation at 12,000 rpm for 15 min, the precipitate was collected and washed twice with deionized water and alcohol. To further remove residues, the product was dispersed in acidic ethanol (Tris-HCl:ethanol = 5:1, V:V) and refluxed for 24 h, followed by drying with a lyophilizer (5417R, Eppendorf) at −50 °C for 24 h.
FITC-labelled MSN: FITC was dissolved in DMSO to prepare a 5 mg/mL FITC solution. Meanwhile, MSN was dispersed in phosphate buffered saline (PBS), then mixed and stirred thoroughly with the FITC solution in a 1:1 ratio. The application of antifade mounting medium combined with light-protected conditions throughout the experiment effectively prevented photobleaching of fluorescent dyes. Finally, unlabelled FITC was removed by centrifugation and FITC-labelled MSN was collected.
MSN@PDA: 100 mL of Tris HCL buffer and deionized water were used to adjust the pH value of 8.5 to provide the alkaline environment required for PDA aggregation, to which 100 mg of PDA was added followed by a rapid addition of 200 mg of MSN. After ultrasonic mixing, the mixture was incubated at room temperature for 4 h. After centrifugation at 12,000×g for 10 min, precipitates were washed twice with deionized water and freeze-dried to collect MSN@PDA.
Dio@MSN@PDA: 30 mg of MSN@PDA was dissolved in 30 mL of ethanol and stirred for 1 h, followed by the addition of 10 mg of Dio. After continued stirring for 30 min, the precipitate was centrifuged at 13,000 rpm for 30 min and washed repeatedly until the supernatant was free of Dio. The collected sediment is dried in a lyophilizer (5417R, Eppendorf) at −50 °C for 24 h.
Dio/siICAM-1@MSN@PDA: Initially, 1 OD of siRNA (mass = 33 μg/2.5 nmol; purity: A260/A280 ≈ 2) was dissolved in 100 μL of diethylpyrocarbonate-treated water to prepare a working solution with a concentration of 0.33 μg/μL (25 μM). Then, Dio@MSN@PDA and siICAM-1 were mixed at 25 °C for 30 min with a mass ratio of 20:1 to produce Dio/siICAM-1@MSN@PDA.
Dio/siICAM-1@MSN@PDA-CD11b: Dio/siICAM-1@MSN@PDA was dissolved with PBS solution (0.02 M, pH = 7.4). After centrifugation at 12,000 rpm for 15 min), 50 μg of EDC and 50 μg of CD11b monoclonal antibody were added to the supernatant and shaken overnight. The next day, the precipitation was collected after centrifugation (12,000 rpm, 15 min) and stored at 4 °C.
2.3. Characterization of nanocomplex
To verify the successful conjugation of FITC, fluorescence spectra of both free FITC and MSN-FITC were acquired using an ultraviolet–visible Spectrophotometer (U-2910, Thermo) with an excitation wavelength of 488 nm. The micromorphology and particle size of MSN, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b were examined by transmission electron microscopy (TEM, F30, Tecnai) and laser particle size analyzer (Microtrac MRB, SYNC), respectively. The nanocomplexes of each group were then assayed for zeta potential using a zeta potentiometer (BeNano 180 Zeta Pro, Bettersize). To observe the changes in molecular structure and functional groups, lyophilized powders of samples in each group were weighed, pressed with KBr, and scanned using a Fourier transform infrared spectroscopy (FTIR, Spectrum 1000, PerkinElmer), with the parameters set at a test wave number of 400 cm−1–4000 cm−1, a resolution of 4 cm-1/s, and a scanning time of 16 s. To evaluate the long-term stability of the nanoparticles, Dio/siICAM-1@MSN@PDA-CD11b was dispersed in PBS (pH7.4) or 10 % fetal bovine serum (FBS, 34080619, Ephraim). Following, the particle size and polydispersity index (PDI) of nanoparticles were tested once a day for seven days using a laser particle size analyzer (Microtrac MRB, SYNC).
2.4. Determination of drug loading efficiency (LE)
1 mg Dio was weighed to produce 1 mg/mL of Dio master batch and prepared into standard working solutions according to different dilution ratios (0, 7.81, 15.62, 31.25, 62.5, 25, 250, 500 μg/mL). Subsequently, Dio was coupled with MSN@PDA in different mass ratios (1:1, 1.5:1, 2:1, 3:1, 4:1) and the optical density (OD) values at 203 nm were detected using a spectrophotometer (U-2910, Thermo). The drug LE of each group was calculated according to the formula below: LE (%) = (Dioori - Diosup)/(MSN@PDA + Dioori - Diosup) × 100 %, where Dioori represents the total weight of Dio originally added, Diosup indicates the mass of free Dio in the supernatant, and MSN@PDA represents the mass of MSN@PDA nanoparticles initially added.
2.5. Agarose gel electrophoresis (AGE)
6-carboxyfluorescein (6-FAM) labelled siRNA was acquired from Guangzhou RiboBio Co., Ltd. Samples were prepared by combining Dio@MSN@PDA and siICAM-1 in a gradient mass ratio of (0:1, 5:1, 10:1, 15:1, 20:1, and 25:1). To assess the migration retardation of siRNA, 2 μL of loading buffer and 6 μL of the Dio@MSN@PDA and siICAM-1 complex with different mass ratios were subjected to AGE at 130 V for 15 min, followed by the visualization of siRNA bands using an ultraviolet imager (Tanon-2500, Tanon).
2.6. In vitro release of Dio
Dio/siICAM-1@MSN@PDA-CD11b was dispersed in PBS, with a pH of 7.4/6.4 and 1 mM H2O2+/−. After shaking the suspension at 37 °C away from light, the supernatant was collected for analysis at time points of 0, 4, 8, 12, 36, 48, and 72 h. Behind this, an equal amount of fresh PBS was replenished to ensure a constant volume within the predetermined time interval. According to the standard curve, the Dio and siICAM-1 release rates (m) were determined using the following formula: m = A/B, where A is the concentration of the drug released in the PBS and B is the initial concentration of the drug loaded in the nanoparticles.
2.7. Cell culture
Cardiomyocytes H9C2 (BH-C601, BoHui Biotechnology) and human peripheral blood neutrophils (PRI-H-00125, Shanghai Zhong Qiao Xin Zhou Biotechnology) were routinely cultured in DMEM (C11995500BT, Gibco) and RCMI-1640 (11875119, Gibco) medium, respectively, supplemented with 10 % FBS and 1 % penicillin/streptomycin (SV30010, Hyclone), respectively. To observe the recruitment of cardiomyocytes to neutrophils, they were co-cultured in this study. Specially, neutrophils were treated with 300 ng/mL of LPS to induce activation [33,34]. Neutrophils were then treated with MSN@PDA-CD11b, free Dio (maintained at a final concentration of 400 nM), free siICAM-1 (maintained at a final concentration of 0.2 μM), Dio@MSN@PDA-CD11b (maintained at a final concentration of 400 nM), siICAM-1@MSN@PDA-CD11b (maintained at a final concentration of 0.2 μM), and Dio/siICAM-1@MSN@PDA-CD11b (maintained at a final concentration of 400 nM) and incubated for 4 h. At the same time, H9C2 cells were treated with 400 μM H2O2 for 24 h to induce damage [34] and finally co-cultured with neutrophils for another duration of 48 h.
2.8. Cellular uptake
Activated neutrophils and cardiomyocytes were incubated with FITC-labelled Dio/siICAM-1@MSN@PDA-CD11b for 2, 4, 8, and 12 h, while nuclei were labelled with DAPI. The fluorescence intensity in the cells was identified using confocal laser scanning microscopy (CLSM, ULTRAVIEW VOX, Perkin Elmer) and flow cytometry (CytoFLEX S, Beckman), respectively, to assess the cellular uptake of the nanoparticles. Fluorescence intensities of CLSM images were quantified with ImageJ. For each sample, relative fluorescence intensity was calculated by subtracting the mean background intensity (cell-free region) from the mean intensity of the region of interest (ROI).
2.9. Quantitative real-time polymerase chain reaction (qPCR)
Total RNA of the cells was extracted using Trizol (15596018, Invitrogen) and reverse transcribed to cDNA. After mixing cDNA, primer, and 2 × SYBR Green PCR Master Mix (A4004M, Lifeint), samples were subjected to PCR reaction (CFX96Touch, Bio-rad) with 40 cycles of 95 °C, 10 min; 95 °C, 12 s; and 60 °C, 40 s. Primer sequences included TGACCGTGAATGTGCTCTCC (forward of ICAM-1), TCCCTTTTTGGGCCTGTTGT (reverse of ICAM-1), CAAGGACAGCAGAGGACCAG (forward of TNF-α), TCCTTTCCAGGGGAGAGAGG (reverse of TNF-α), AGCTTCAGCCCCAGGAAATC (forward of GAPDH), and GACATACTGCTGGGCCAGTT (reverse of GAPDH). Using GAPDH as the housekeeping gene, the relative mRNA expressions of target genes were calculated.
2.10. Cell counting kit-8 (CCK-8)
Cardiomyocytes that reached the logarithmic growth phase were collected for resuspension and inoculated into 96-well plates (2000 cells/well) for culture. Subsequently, cells were co-cultured with treated neutrophils as described above for 48 h, after which 10 μL of CCK-8 reaction solution (C0037, Beyotime) was added. After continuing the incubation for 2 h, the absorbance at 450 nm was measured and detected by a microplate reader (DR-3518G, Wuxi Hiwell Diatek) to assess the viability of the cells.
2.11. Cell apoptosis
After co-culture with neutrophils, the cardiomyocytes of each group were collected for washing and made into cell suspension. Then, the suspension cells were mixed with 5 μL Annexin V-FITC (C1062S, Beyotime) and incubated in a place protected from light for 15 min, followed by the addition of 10 μL of PI staining solution and continued incubation for 10 min. The fluorescence intensity of apoptotic cells was detected by flow cytometry (CytoFLEX S, Beckman) and quantified using CELL Quest software.
2.12. ROS detection
After co-culture for 48 h, ROS levels in H9C2 cells of each group were detected using a standard kit (S0033M, Beyotime). Briefly, DCFH-DA was prepared with a final concentration of 10 μmol/L by dilution of serum-free medium at 1:1000. Cells in each group were then collected, washed, and incubated with a probe for 20 min. Furthermore, cells were washed thrice with serum-free medium to remove the dissociative probes. Finally, cells were detected by CLSM (ULTRAVIEW VOX, Perkin Elmer) at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. Fluorescence intensity was quantified using ImageJ software following the protocol described in section 2.8.
2.13. Detection of mitochondrial superoxide
In this study, Mitochondrial Superoxide Assay Kit with MitoSOX Red (S0061S, Beyotime) was used to detect mitochondrial superoxide levels in H9C2 cells. According to the product instructions, the MitoSOX Red was diluted with HBSS buffer to prepare the probe working solution. The mixture was then sufficiently covered with crawler-grown cardiomyocytes and incubated for 10 min at 37 °C, protected from light. Finally, cells were rinsed, re-stained, and sealed for observation and recording of mitochondrial superoxide. Fluorescence intensity was quantified using ImageJ software following the protocol described in section 2.8.
2.14. Detection of mitochondrial membrane potential (MMP)
The level of MMP in cardiomyocytes was detected using a kit (C2006, Beyotime). Firstly, the JC-1 staining working solution was configured according to the ratio of 8 mL of ultrapure water for every 50 μL of JC-1. The H9C2 cells in each group were then collected for resuspension, and 0.5 mL of JC-1 staining working solution was added, followed by the incubation at 37 °C for 20 min. During this process, JC-1 staining buffer was prepared at a ratio of 4 mL of distilled water for every 1 mL of JC-1. After incubation, cells were centrifuged at 600 g for 3 min at 4 °C to discard the supernatant. Finally, cells were washed twice with JC-1 staining buffer, resuspend, and measured for fluorescence intensity in a CLSM (excitation wavelength: 525 nm; emission wavelength: 590 nm). Quantitative fluorescence analysis was performed using ImageJ software. Following background subtraction, mean fluorescence intensities were measured in both green and red channels. The membrane potential was calculated as the ratio of red (aggregate) to green (monomer) fluorescence intensity.
2.15. Enzyme linked immunosorbent assay (ELISA)
The cell sample is mashed with an appropriate amount of saline. After 1000×g centrifugation for 10 min, the supernatant was collected. According to the standard procedure of ELISA kits (TNF-α, PT518, Beyotime; IL-6; PI330, Beyotime; IL-1β, PI305, Beyotime), the preparation of standard product and the Streptavidin-HRP reaction were carried out. The OD value of each well was measured at 450 nm to calculate the content of TNF-α, IL-6, and IL-1β in cardiomyocytes.
2.16. Animal experiments
All C57BL/6J male mice aged 10 weeks were purchased from the Experimental Animal Center of Yangzhou University. To establish the MI model in vivo, mice were anesthetized with isoflurane gas, and the chest of each mouse was opened laterally to expose the heart under sterile conditions. Then, the left anterior descending coronary artery was ligated 2–3 mm below the starting point. Following, the chest was closed, the air in the chest cavity was squeezed out, and the skin incision was sutured. After resuming spontaneous breathing, the mouse was extubated and machine-assisted respiration was discontinued. The Sham group was subjected to the same surgical procedure but without ligation of the coronary arteries. All animal experiments followed the ARRIVE guidelines and were approved by the Experimental Animal Ethics Committee of Yangzhou University (No. 202406027).
To investigate neutrophil recruitment to MI sites, we established an MI model and characterized neutrophil infiltration within 48 h post-modeling. Twenty-one C57BL/6J male mice were randomly allocated into two groups: sham (n = 3) and MI (n = 24) groups. At predetermined time points (0, 3, 6, 12, 24, and 48 h post-MI), three mice per time point were euthanized for cardiac tissue collection, followed by the quantification of CD11b+Ly6G+ neutrophil infiltration using flow cytometry.
For in vivo pharmacokinetic evaluation of Dio, six mice were used to establish MI model and divided into two treatment groups (n = 3 per group): free Dio (80 mg/kg, intravenous injection) and Dio-siICAM-1@MSN@PDA-CD11b nanoparticles (equivalent Dio dose of 80 mg/kg with 5 μM siICAM-1). Then, blood samples (200 μL) were collected via retro-orbital venous plexus at 0.083, 0.125, 0.25, 0.5, 1, 3, 6, 12, 24, and 48 h post-injection. Plasma was separated by centrifugation (4 °C, 4000 rpm, 10 min) for Dio concentration analysis.
To assess in vivo biodistribution of the nanoparticles, 12 mice were procured and randomly assigned into four groups (n = 3): A (Dio-siICAM-1@MSN@PDA), B (Dio-siICAM-1@MSN@PDA + MI), C (Dio-siICAM-1@MSN@PDA-CD11b), and D (Dio-siICAM-1@MSN@PDA-CD11b + MI). Mice in groups B and D underwent MI surgery before nanoparticle administration. Mice in the A/B and C/D groups received intravenous injections of 1 mg/kg of FITC-labelled Dio/siICAM-1@MSN@PDA and Dio/siICAM-1@MSN@PDA-CD11b, respectively. After 24 h, organs were harvested for fluorescence imaging and neutrophil colocalization analysis.
Fifty-four C57BL/6J male mice (totally nine groups and six mice for each group) were used to evaluate the therapeutic efficiency of nanoparticles on cardiac repair in vivo. MI was induced in treatment groups prior to therapeutic administration. After the model construction, MSN@PDA-CD11b, free Dio, free siICAM-1, Dio@MSN@PDA-CD11b, siICAM-1@MSN@PDA-CD11b, and Dio/siICAM-1@MSN@PDA-CD11b were injected into the mice through the tail vein for treatment. The final concentration of Dio was maintained at 80 mg/kg/d and the final concentration of siICAM-1 was 5 μM in each treatment group. Mice in the control, sham, and MI model groups were injected with normal saline instead. All mice were treated thrice on 0, 3, and 6 days after modeling [35]. On day 4, cardiac tissues were harvested from three randomly selected mice per group for analysis of neutrophil infiltration and molecular alterations. On day 28, the remaining three mice of each group were assayed for transthoracic echocardiography, followed by the calculation of left ventricular ejection fraction (LVEF) and left ventricular fraction shorting (LVFS) to assess their cardiac functions. Finally, these mice were anesthetized and executed to collect heart, liver, spleen, lung, and kidney tissues, as well as blood samples for subsequent experiments.
2.17. In vivo biodistribution
To monitor the biodistribution of nanoparticles in vivo, mice in Groups A–D were treated as described in Section 2.16. Fluorescence imaging was performed using an IN-VIVO imaging system (Caliper Life Sciences) with excitation/emission wavelengths of 488 and 500–550 nm, respectively, to detect FITC-labelled nanoparticles. Fluorescence intensity was detected at 3, 6, 12, and 24 h after injection. At 24 h, mice were euthanized and major organs (heart, liver, spleen, lung, and kidney) were harvested for ex vivo fluorescence quantification. Quantitative analysis was performed using ImageJ software. Net fluorescence in each organ was calculated as the ROI intensity minus the background intensity. Cardiac targeting efficiency was then evaluated via the heart-targeting index (HTI), defined as the ratio of the net fluorescence in the heart (photons/sec/cm2/sr) to that in the liver (photons/sec/cm2/sr).
2.18. Quantification of plasma Dio by high performance liquid chromatography (HPLC)
To quantify Dio concentration in plasma, 100 μL of samples was successively mixed with 50 μL 0.1 N NaOH (37 °C for 15 min), 50 μL 0.1 N HCl, and 100 μL methanol (1922, Tedia). Following, the mixture was vortexed for 2 min, sonicated, and centrifuged at 4000 rpm for 5 min. The supernatant was then reconstituted in 100 μL methanol. The resulting solution was filtered through a 0.45-μm membrane and analyzed on an Agilent 1260 HPLC system equipped with a ChromCore C18 column (NanoChrom). Chromatographic separation was achieved using a gradient elution of (A) acetonitrile (9017, JT Baker) and (B) aqueous 0.2 % phosphoric acid (095233, Fisher) at 30 °C. During this process, the flow rate was 1 mL/min, the injection volume was 10 μL, and the detection wavelength was 203 nm.
2.19. Detection of neutrophil infiltration
The heart tissue was extracted under sterile conditions, cut into small pieces, and placed on a sieve. After complete grinding, the sieve was rinsed using whole blood and tissue diluent to collect the cell suspension. By sedimentation, the lower layer of erythrocytes was removed and the upper suspension was spread flat on top of the separation solution (p2430, Solarbio). After density gradient centrifugation at 600–1000 g for 25–30 min, the neutrophil-rich lower white layer of the centrifuge tube was carefully aspirated into a new centrifuge tube, washed, and centrifuged at 250 g for 10 min. The precipitate was then collected to prepare a cell suspension. Then, 3–5 μL of CD11b+-FITC and Ly6G+-PE antibodies were added into the cells and incubated away from light for 20–30 min. Following washing and resuspension, cellular fluorescence was quantified using flow cytometry.
2.20. In vivo co-localization of nanoparticles with neutrophils
Paraffin-embedded cardiac tissue sections were prepared following standard histological protocols. After permeabilization and blocking, tissue sections were incubated with anti-CD11b (1:100) and anti-Ly6G (1:100) antibodies overnight at 4 °C in the dark. The following day, the primary antibodies were removed, and the sections were washed three times with PBS. Sections were then incubated for 1 h at room temperature with either goat anti-rabbit IgG H&L (Alexa Fluor® 647,1:500) or goat anti-mouse lgG H&L (Alexa Fluor® 594, 1:500) antibodies. Following further washes, nuclei were counterstained with DAPI (5 min) before mounting with antifade medium. The fluorescence intensity of slices was examined under a fluorescence microscope and quantified using ImageJ as described in Section 2.8. The co-localization ratio of FITC-labelled nanoparticles with neutrophils was calculated as the integrated fluorescence intensity of the red–green–yellow overlapping regions divided by the integrated fluorescence intensity of the red–yellow overlapping regions.
2.21. Western blotting
Western blotting was carried out using standard procedures to detect protein expression levels of ICAM-1, TNF-α, and NF-κB/STAT3/p38 pathway in myocardial tissues. Briefly, lysates (P0013B, Beyotime) were added to tissues to release total proteins for quantification. After sampling, sodium dodecyl sulfate polyacrylamide gel electrophoresis was carried out to separate proteins. Then, proteins from the gel were transferred to a polyvinylidene fluoride membrane (FFP24, Beyotime) and incubated overnight with primary antibody working solution (anti-ICAM-1, 1:1000; anti-STAT3, 1:1000; anti-p-STAT3, 1:1000; anti-NF-κB, 1:1000; anti-p-NF-κB, 1:1000; anti-p38, 1:1000; anti-p-p38, 1:1000; anti-TNF-α, 1:1000; anti-GAPDH, 1:10000). The next day, the membranes were washed and then continued with the addition of the secondary antibody working solution for a 1 h's incubation at room temperature. After cleaning again, enhanced chemiluminescence (P1000, ApplyGen) was added for exposure and color development. Finally, the film was scanned and archived, while ImageJ was used to quantify the gray values of the bands. The relative expression of target proteins was calculated using GAPDH as an internal reference.
2.22. Immunohistochemistry (IHC)
Myocardial tissues of mice in each group were prepared into paraffin sections by fixation, washing, dehydration, transparency, wax dipping, and embedding. After dewaxing hydration and antigen repair, endogenous peroxidase activity was further blocked in the sections. Subsequently, primary antibodies of ICAM-1, TNF-α, and GR1 configured at a dilution ratio of 1:200 were added to the sections and incubated at 4 °C overnight. Afterward, the secondary antibody was configured at a dilution ratio of 1:2000 and incubated on the sections for 10 min. After cleaning the sections for three times, DAB (P0202, Beyotime) was added for color development, and the sections were counterstained with hematoxylin for 3 min. Finally, the sections were dehydrated and sealed for observation and recording under the microscope.
2.23. Masson's trichrome staining
Mouse myocardial tissues were prepared into paraffin sections, stained with hematoxylin for 5 min, and washed according to the standard procedure of Masson's Trichrome Stain Kit (G1340. Solarbio). After staining with Lichun red acidic red staining solution for 5 min, the sections were rinsed and then treated with 1 % phosphomolybdic acid aqueous solution for 50 s. Afterward, the sections were stained with solid green staining for 5 s. After washing and drying, the slices were sealed, observed, and recorded under a microscope. The resulting images were analyzed using ImageJ to calculate the infarct size.
2.24. Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labelling (TUNEL)
Sections of mouse heart tissue were routinely dewaxed and hydrated. According to the instructions of the TUNEL kit (C1091, Beyotime), the sections were first digested with proteinase K working solution, and then incubated with the mixture (5 μL TdT enzyme, 45 μL fluorescent labeling solution, and 50 μL TUNEL detection solution) for 60 min. After sealing with antifade mounting medium, the sections were observed and recorded under a fluorescence microscope. Fluorescence intensity was quantified using ImageJ software following the protocol described in section 2.8.
2.25. In vivo safety evaluation
Liver, spleen, lung, and kidney tissues from each experimental group were collected, fixed and processed into paraffin-embedded sections. Tissue sections were stained with hematoxylin for 5 min and eosin for 1–2 min (HE staining) using standard protocols. Following dehydration and clearing, the sections were mounted and examined under a light microscope to evaluate potential pathological alterations. For biochemical analyses, blood samples were centrifuged at 2000 g for 15–20 min to obtain serum. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine (CRE) were quantified using an automated biochemical analyzer (3500, HITACHI) to assess hepatic and renal function.
2.26. Statistical analysis
All data was exhibited as mean ± standard deviation and processed for analysis in GraphPad 10.1.2. All experiments were performed with at least three independent biological replicates. Differences between two groups were analyzed using unpaired t-test. Comparison between groups was implemented using one-way analysis of variance, followed by Tukey's post-hoc test. The statistical significance was defined when P < 0.05.
3. Results
3.1. Synthesis and characterization of Dio/siICAM-1@MSN@PDA-CD11b
In this study, MSN was synthesized by TEOS, CTAC, and TEA, and polymerized PDA under alkaline environment to achieve ROS and pH-responsive properties. Subsequently, Dio was encapsulated in the pores of MSN@PDA by free diffusion and siICAM-1 was then loaded by electrostatic adsorption. Finally, CD11b was coupled with Dio/siICAM-1@MSN@PDA to target neutrophils. The preparation process of nanoparticles is shown in Fig. 2A. Fluorescence spectroscopy revealed a distinct FITC emission peak at 520–550 nm for MSN-FITC (Fig. 2B), confirming the successful conjugation of FITC to the nanoparticles. To characterize the nanomaterials, they were subjected to TEM, which suggested clear mesoporous structure of the MSN, as well as obscure mesoporous structure and observed layer of Dio/siICAM-1@MSN@PDA (Fig. 2C). Meanwhile, the particle sizes of MSN, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b gradually increased to 110.00 ± 0.20, 121.37 ± 0.15, and 132.37 ± 0.15 nm, respectively (Fig. 2D). FTIR suggests that MSN, Dio@MSN@PDA, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b have individual peaks of MSN at wavelengths around 1100 cm−1, which is due to the SI-O-Si antisymmetric stretching vibration peak generated by the vibration between Si and O atoms in the MSN material [36]. In addition, the characteristic peaks observed in Dio@MSN@PDA, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b at wavelengths of 1061 cm−1, 2945 cm−1 and 3412 cm−1 are due to C-O-C stretching in the ring of Dio, symmetric/asymmetric stretching C-H vibrations, and O-H vibrations in CH3, respectively. They also showed characteristic peaks of PDA at around 3200-3600 cm−1 and 1500 cm−1 [37], indicating the presence of -OH groups and C=O (Fig. 2E). Zeta potential results suggested that the potential of MSN was −19.67 ± 1.70 mV, which was significantly increased to 9.67 ± 1.25 mV after wrapping positively charged PDA. Dio and siICAM-1 were then sequentially adsorbed, which resulted in a decrease in the charge to −14.00 ± 1.00 and −20.67 ± 2.08 mV, respectively. After labeling CD11b, the Dio/siICAM-1@MSN@PDA-CD11b potential increased to −5.33 ± 1.25 mV (Fig. 2F).
Fig. 2.
Synthesis and characterization of Dio/siICAM-1@MSN@PDA-CD11b. (A) Schematic illustration of the synthetic process of Dio/siICAM-1@MSN@PDA-CD11b. (B) The fluorescence spectroscopy of FITC and MSN-FITC. (C) TEM demonstrating the microstructure of MSN, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b. Scale bar: 200 nm. (D) Particle sizes of MSN, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b. (E) The molecular structure and functional groups of MSN, Dio, PDA, Dio@MSN@PDA, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b were detected by FTIR. (F) Zeta potential changes of MSN, MSN@PDA, Dio/siICAM-1@MSN, Dio/siICAM-1@MSN@PDA, and Dio/siICAM-1@MSN@PDA-CD11b. (G) LE of Dio at different mass ratios. (H) Migration block of siICAM-1 at different mass ratios. (I) Changes in the size and PDI of nanoparticles dispersed in PBS and FBS over a 7-day period. (J) The release of Dio and siICAM-1 under pH7.4/6.4 and H2O2+/−. ∗P < 0.05, ∗∗P < 0.01. N = 3 for each experiment.
The absorbance values under different mass ratios suggest that the LE of Dio elevated with the increase of mass ratio, reaching a maximum of 52 % at the ratio of 4:1 (Fig. 2G). AGE indicated that the migration of siICAM-1 was progressively retarded at mass ratios of 0:1, 5:1, 10:1, 15:1, and completely retarded until 20:1 (Fig. 2H). The Dio/siICAM-1@MSN@PDA-CD11b nanocomplex demonstrated excellent long-term stability, as evidenced by maintaining consistent size and PDI in various solutions over a 7-day observation period (Fig. 2I). Considering the ROS and pH response properties of Dio/siICAM-1@MSN@PDA-CD11b, this study set the conditions of pH7.4/6.4 and H2O2+/− to evaluate the release of Dio and siICAM-1. The results suggest that the release rates of Dio and siICAM-1 in the environment of pH6.4 and H2O2+ were significantly higher than those of other groups, reaching a peak at 24 h and remaining stable until 80 h (Fig. 2J). The above results suggested that Dio/siICAM-1@MSN@PDA-CD11b was successfully constructed and was sensitive to ROS and pH stimulation.
3.2. In vitro intracellular uptake and molecular changes
CD11b is a surface marker of neutrophils [38], and its antibody confers the ability for nanoparticles to target neutrophils. To confirm the targeting of Dio/siICAM-1@MSN@PDA-CD11b to neutrophils, the nanoparticles were labelled with FITC. CLSM and flow cytometer were then applied to detect the in vitro intracellular uptake of nanoparticles by cardiomyocytes and neutrophils. The results suggested that the fluorescence intensity of neutrophils uptake of Dio/siICAM-1@MSN@PDA-CD11b increased from 4 h, and was significantly stronger than that of H9C2 cells (Fig. 3A and B). In addition, we also observed a significant decrease in siICAM-1 mRNA levels and protein levels of NF-κB/STAT3/p38-MAPK pathway (p-NF-κB/NF-κB, p-STAT3/STAT3, and p-p38/p38) in neutrophils treated with Dio/siICAM-1@MSN@PDA-CD11b, compared to the rest of treated groups (Fig. 3C and D). Meanwhile, both Dio and siICAM-1 were able to down-regulate the expression of ICAM-1 and inactivate the NF-κB/STAT3/p38-MAPK pathway, with their combination demonstrating superior efficacy than free Dio and free siICAM-1. The results suggested that Dio/siICAM-1@MSN@PDA-CD11b can effectively target neutrophils to reduce the expression level of ICAM-1 and inactivate the NF-κB/STAT3/p38-MAPK pathway.
Fig. 3.
Intracellular uptake of Dio/siICAM-1@MSN@PDA-CD11b in vitro. (A–B) Uptake of Dio/siICAM-1@MSN@PDA-CD11b by neutrophils and cardiomyocytes at different time points was analyzed by CLSM (A) and flow cytometry (B). Scale bar: 10 μm. (C) The mRNA expression levels of ICAM-1 in neutrophils under different treatment groups. (D) The protein expression of NF-κB/STAT3/p38-MAPK pathway in neutrophils under different treatment groups. ∗P < 0.05, ∗∗P < 0.01. N = 3 for each experiment.
3.3. Neutrophil-mediated protective effects on cardiomyocytes in vitro
MI-triggered cardiomyocyte injury promotes neutrophil recruitment and thus triggers an inflammatory response, and these changes in the immune microenvironment will in turn exacerbate disease progression in MI [39]. To further evaluate the effectiveness of nanoparticles in treating MI in vitro, treated neutrophils were co-cultured with H2O2-induced H9C2 to observe the changes in cardiomyocyte function (Fig. 4A). The results suggested that the combined use of Dio, siICAM-1, and MSN@PDA-CD11b significantly restored the proliferation of damaged cardiomyocytes while inhibiting the abnormal apoptosis, which was superior to that of the single Dio, siICAM-1, or MSN@PDA-CD11b-treated group (Fig. 4B and C). Meanwhile, this study also observed the significant increase of ROS in H2O2-induced H9C2 cells, which were significantly alleviated by Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophils, and the ROS inhibition effect was superior to those treated by single Dio, siICAM-1, and MSN@PDA-CD11b (Fig. 4D).
Fig. 4.
Effect of Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophils on H2O2-induced cardiomyocyte injury in vitro. (A) Schematic illustration of the co-culture assay in vitro. (B–D) Effects of nanoparticles treated neutrophils on proliferation (B), apoptosis (C), and ROS levels (D) of H2O2-induced cardiomyocytes. Scale bar: 10 μm. (E–F) Effect of co-culture with Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophil on H2O2-induced mitochondrial superoxide (E) and MMP (F) levels in H9C2 cells. Scale bar: 10 μm. (G) Effect of the addition of nanoparticle-treated neutrophil on inflammatory cytokines in damaged cardiomyocytes. ∗P < 0.05, ∗∗P < 0.01. N = 3 for each experiment.
Impaired mitochondrial function and inflammatory responses are common in MI-triggered cardiomyocyte damage. To further observe the effects of nanoparticle-targeted neutrophils on the mitochondrial function of H2O2-induced H9C2 cells, the present study examined the levels of superoxide, as well as MMP in each group of cardiomyocytes using relevant kits. The results suggested that H2O2-induced cardiomyocytes exhibited significantly elevated levels of superoxide, which could be significantly suppressed by Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophils, and the effect was superior to that of other treatment groups (Fig. 4E). In contrast, MMP levels were significantly elevated in damaged H9C2 cells, which were significantly suppressed with the addition of Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophil (Fig. 4F). Meanwhile, the levels of inflammatory cytokines in H9C2 cells were also detected by ELISA. The results suggested that the levels of IL-β, IL-6, and TNFα were significantly elevated in H2O2-induced cardiomyocytes and tended to be significantly decreased after the addition of Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophils (Fig. 4G). These findings illustrated that Dio/siICAM-1@MSN@PDA-CD11b-treated neutrophil could promote myocardial repair via coordinated improvement in cellular viability, mitochondrial function, and inflammation response.
3.4. In vivo biodistribution and pharmacokinetics of nanoparticles
To evaluate the efficacy of Dio/siICAM-1@MSN@PDA-CD11b on cardiac function repair in vivo, a MI mouse model was constructed in this study. Post-MI induction, CD11b+Ly6G+ neutrophil infiltration in the cardiac tissues increased progressively, peaking at 24 h and maintaining a high level until 48 h (Fig. 5A). Plasma pharmacokinetic profiling demonstrated that Dio/siICAM-1@MSN@PDA-CD11b achieved higher Dio concentrations compared with free Dio at all time points and showed prolonged plasma clearance. The nanoparticle formulation extended the circulation half-life (t1/2) of Dio from 4.46 h to 8.71 h (Fig. 5B). Following, the biodistribution of FITC labelled Dio/siICAM-1@MSN@PDA and Dio/siICAM-1@MSN@PDA-CD11b in mice was observed using in vivo imaging. As results, the enrichment of Dio/siICAM-1@MSN@PDA-CD11b in MI mice was higher than that in other groups and reached the maximum at 6 h after treatment (Fig. 5C). Ex vivo organ imaging corroborated these findings, with hearts from group D exhibiting significantly higher fluorescence intensity than all other groups. Quantitative analysis yielded a markedly elevated HTI for Dio/siICAM-1@MSN@PDA-CD11b (Fig. 5D). Immunofluorescence further revealed substantially enhanced co-localization of FITC-labelled nanoparticles with CD11b+Ly6G+ neutrophils in group D compared with groups A-C (Fig. 5E). These findings illustrated that CD11b-labelled nanoparticles could better target the damaged myocardial tissue in MI mice. The correlation between neutrophil infiltration and nanoparticle pharmacokinetics provides critical guidance for optimizing treatment regimens to disrupt neutrophil-driven inflammatory cascades.
Fig. 5.
In vivo biodistribution and pharmacokinetics of nanoparticles. (A) The neutrophil infiltration into cardiac tissue within 48 h post-MI induction. (B) Prolonged blood circulation time and blood circulation half-time (t1/2) of Dio and Dio/siICAM-1@MSN@PDA-CD11b. (C) The whole-body fluorescence distribution of nanoparticles within 24 h post-administration. (D) Ex vivo fluorescence intensities in major organs harvested 24 h after treatment. (E) Co-localization of FITC-labelled nanoparticles with CD11b+Ly6G+ neutrophils in infarcted myocardium. Scale bar: 20 μm ∗P < 0.05, ∗∗P < 0.01. N = 3 for each experiment.
3.5. Nanoparticle-induced neutrophil infiltration blockade and molecular changes in vivo
At the day 4 timepoint, all experimental groups underwent quantitative assessment of neutrophil infiltration and molecular alterations in cardiac tissues. Initially, flow cytometry was performed to assess CD11b+ neutrophil infiltration within myocardial tissues. As results, the level of neutrophil infiltration was significantly elevated in MI mice, but was significantly reduced and converged with normal mice after the treatment of Dio/siICAM-1@MSN@PDA-CD11b (Fig. 6A). IHC also suggested that the GR1(high) neutrophil recruitment was significantly elevated in myocardial tissue of MI mice, which were significantly reduced with the addition of Dio/siICAM-1@MSN@PDA-CD11b (Fig. 6B). Furthermore, qPCR, western blotting, and IHC were carried out to estimate the expression of ICAM-1 and TNF-α in myocardial tissues of each group. Consistently, ICAM-1 and TNF-α were significantly overexpressed in the myocardial tissues of MI mice, but the treatment of Dio/siICAM-1@MSN@PDA-CD11b significantly reversed this trend and reduced both mRNA and protein levels (Fig. 6C–E). Moreover, Dio/siICAM-1@MSN@PDA-CD11b significantly attenuated the cardiac levels of p-NF-κB/NF-κB, p-STAT3/STAT3, and p-p38/p38 in MI mice (Fig. 6F), indicating the potent blockade of NF-κB/STAT3/p38-MAPK pathway. Consistent with the in vitro findings, this nanocomplex exhibited a more pronounced inhibitory effect on the neutrophil infiltration and expressions levels of ICAM-1, TNF-α, and the NF-κB/STAT3/p38-MAPK pathway than any other treatment groups (Fig. 6A–F). Therefore, Dio/siICAM-1@MSN@PDA-CD11b can attenuate neutrophil recruitment and reduce the levels of ICAM-1, inflammatory factors, and NF-κB/STAT3/p38-MAPK pathway in damaged myocardial tissues of MI mice.
Fig. 6.
Nanoparticles-induced molecular changes in vivo. (A–B) Flow cytometry (A) and IHC (B) demonstrating the changes in neutrophil levels in myocardial tissues after the treatment with nanomaterials in each group of mice, respectively. Scale bar: 20 μm. (C–E) The mRNA and protein levels of ICAM-1 and TNF-α in myocardial tissues of MI mice after the treatment of nanoparticle were detected by qPCR (C), western blotting (D), and IHC (E). Scale bar: 50 μm. (F) Protein levels of NF-κB/STAT3/p38-MAPK pathway in myocardial tissues of MI mice after the treatment of nanoparticle. ∗P < 0.05, ∗∗P < 0.01. N = 3 for each experiment.
3.6. In vivo evaluation on therapeutic efficiency of nanoparticles on cardiac repair
Echocardiography was carried out to evaluate the ability of nanoparticles to repair cardiac function of MI mice in vivo. It revealed that mice in the control and sham groups exhibited normal left ventricular (LV) cavity geometry, wall thickness, and wall-motion waveforms. In contract, mice in the MI group showed obvious anterior wall thinning, apical spherical dilation, flattened anterior wall motion, and global waveform amplitude depression. MI mice treated with either MSN@PDA-CD11b or siICAM-1 exhibited anterior-wall thinning and waveform depression comparable to the MI group, without any amelioration of apical dilation. Dio treatment partially restored anterior-wall thickness, attenuated apical expansion, improved anterior-wall contraction, but remained delayed relative to the posterior wall. Targeted delivery of siICAM-1@MSN@PDA-CD11b and Dio@MSN@PDA-CD11b partially normalized mid-anterior-wall motion and reduced apical dyskinesia, enhancing anterior–posterior synchrony, although apical waveforms remained irregular. Notably, Dio-siICAM-1@MSN@PDA-CD11b restored LV morphology to near-Sham status (Fig. 7A). Furthermore, Dio/siICAM-1@MSN@PDA-CD11b treatment significantly increased LVFS from 13.23 % to 42.01 % and restored LVEF from 41.33 % to 68 % (Fig. 7B). In addition, we also found that the myocardial infarct area and the number of cardiomyocyte apoptosis were significantly higher in MI mice than in control and sham groups, but these abnormalities were significantly improved with the treatment of Dio/siICAM-1@MSN@PDA-CD11b (Fig. 7C and D). These results suggested that Dio/siICAM-1@MSN@PDA-CD11b may exert a therapeutic effect in treating MI and repairing cardiac function.
Fig. 7.
In vivo assessment of Dio/siICAM-1@MSN@PDA-CD11b′s effects on injured myocardial tissue and cardiac function in MI mice. (A) Echocardiogram demonstrating the waveform characteristics of heart in each group of mice. (B) Differences in LVEF and LVFS between each group of mice. (C–D) Masson's trichrome staining (C, scale bar: 20 μm) and TUNEL (D, scale bar: 50 μm) depicting the differences in myocardial infarct area and the number of apoptotic cardiomyocytes in each group of mice, respectively. ∗P < 0.05, ∗∗P < 0.01. N = 3 for each experiment.
3.7. In vivo biosafety assessment
To evaluate the in vivo biosafety of the nanoparticles, we performed histopathological examination of major organs (liver, spleen, lung, and kidney) via HE staining. Histological analysis revealed no apparent pathological alterations among all experimental groups (Fig. 8A). Furthermore, serum biochemical analyses demonstrated that ALT, AST, BUN, and CRE levels remained no significant differences across all groups (Fig. 8B), indicating unimpaired hepatic and renal functions. These data confirmed the favorable in vivo biosafety profile of the engineered nanoparticles.
Fig. 8.
In vivo biosafety assessment of Dio/siICAM-1@MSN@PDA-CD11b. (A) HE staining revealing morphological alterations in major organs (liver, spleen, lung, and kidney) across experimental groups. Scale bar: 50 μm. (B) The serum levels of hepatic (ALT and AST) and renal (BUN and CRE) function indices among all groups. N = 3 for each experiment.
4. Discussion
Under alkaline environment, this study polymerized dopamine on the surface of the synthesized MSNs to endow the nanomaterials with ROS/pH dual-responsive properties. The results of drug release suggested that Dio/siICAM-1@MSN@PDA-CD11b had the highest release rates of Dio and siICAM-1 under MI simulated environment of pH6.4 and H2O2+ in vitro. PDA can be stabilized in the environment of blood circulation or extracellular delivery (pH 7.4), but rapidly decomposes under acidic conditions [40]. Hhatre et al. [41] also demonstrated that PDA-loaded nanoparticles, under physiological conditions of pH 5.5, showed a drug release rate of approximately 50 %, which was significantly higher than that of pH 7.4. After further adsorption of Dio and siICAM-1, this study also labelled CD11b on nanoparticles to recognize and target neutrophils. CD11b, a family member of the β-integrin adhesion protein, is highly expressed in innate immune cells, especially neutrophils [42]. More importantly, CD11b assisted the exosmosis of inflammation and the migration of neutrophils to the site of infection, while generating ROS [43,44]. Thus, labelling CD11b not only targets neutrophils but also prevents their infiltration in the lesions of inflammation. As expected, the uptake fluorescence of Dio/siICAM-1@MSN@PDA-CD11b in neutrophils was significantly higher than that of H9C2, while the drug was released in response to ROS and pH stimulation for the purpose of promoting myocardial repair.
In myocardial injury, ROS-induced oxidative stress occurs throughout the pathogenesis, while oxidative stress and inflammation promote each other, jointly aggravating MI injury [45,46]. The release of inflammatory factors will further stimulate the generation of ROS, leading to a vicious cycle of oxidative stress and inflammation [47]. Dio has anti-inflammatory and antioxidant activities against ischemia/reperfusion injury in lung and intestine [48,49]. In addition, Dio can also inhibit platelet activation, oxidative stress, and inflammation during myocardial ischemia-reperfusion in rats, thereby ameliorating arrhythmia after MI [50,51]. Consistent with the above studies, the inhibition of inflammatory factors as well as ROS levels in damaged cardiomyocytes by Dio was observed, in both in vitro and in vivo MI mice of this study. In fact, within the first few minutes of MI, oxidative stress rapidly leads to abnormal mitochondrial function and triggers a buildup of lactate and a decrease in pH due to metabolic abnormalities; these changes rapidly cause apoptosis in cardiomyocytes [52]. This also emphasizes the importance of mitochondrial quality control in maintaining cardiomyocyte homeostasis [53]. This study found that Dio could reduce the level of mitochondrial superoxide and restore MMP in MI model. The team from Nanjing Medical University further presented evidence that Dio can attenuate MI by improving mitochondrial dysfunction and maintaining mitochondrial dynamics [54]. Hence, Dio acts as a natural antioxidant to protect the myocardium from ischemic injury by resisting inflammatory responses and mitochondrial dysfunction.
ICAM-1 is a member of the immunoglobulin superfamily. Its involvement in the pathology of cardiac diseases is associated with the promotion of neutrophil infiltration and microvascular coronary slow flow [15,55]. In the present study, siICAM-1 could act as a gene drug to effectively improve inflammation and mitochondrial function in damaged cardiomyocytes. More importantly, siICAM-1 in combination with Dio was superior to free Dio and free siICAM-1. To explain this, Wu et al. [56] suggested that Dio inhibits inflammatory responses and treats atherosclerosis by decreasing ICAM-1 expression. Dio also alleviated thioacetamide-induced acute liver injury by downregulating ICAM-1 [57]. Therefore, we speculated that both Dio and siICAM-1 could achieve the purpose of inhibiting the ICAM-1 expression, thereby alleviating the inflammatory response in MI. Furthermore, ICAM-1 can help neutrophils to cross the endothelial barrier and adhere to the endothelial surface during inflammation, thus exerting its pro-inflammatory mediator role [58]. Mechanistically, excessive neutrophil infiltration is highly associated with activation of the NF-κB/STAT3/p38-MAPK signaling pathway [59]. Both NF-κB and p38-MAPK serve as potent inducers of proinflammatory cytokines, thereby promoting cardiomyocyte apoptosis [60,61]. It was reported that miR-150-5p directly bind to the 3′-UTR of ICAM-1, thereby reducing ICAM-1 expression, attenuating p-p38 levels, and alleviating inflammation [62]. Growing evidences also demonstrated that Dio effectively suppresses NF-κB activation [63,64] while concurrently inhibiting the STAT3 signaling pathway [65,66]. Therefore, in the process of alleviating myocardial injury by downregulation of ICAM-1, there may be a gradual restoration of mitochondrial function that inhibits the inflammatory response to MI by blocking the NF-κB/STAT3/p38-MAPK pathway.
Although the biosafety and efficacy of Dio/siICAM-1@MSN@PDA-CD11b were elaborated via in vivo and in vitro experiments of this study, its long-term safety margins still need to be confirmed by clinically based data. In addition, how to produce Dio/siICAM-1@MSN@PDA-CD11b in large quantities while maintaining the quality control and stability of the product still needs to be heavily discussed before clinical application.
5. Conclusion
Dio/siICAM-1@MSN@PDA-CD11b constructed in this study could target neutrophils and block their migration into MI myocardial tissues. Meanwhile, the loading of PDA realized the response of nanoparticles to ROS and pH at the lesion for the rapid release of drugs. Co-delivery of Dio and siICAM-1 demonstrated the potential to improve cardiomyocyte function both in vitro and in vivo, while effectively ameliorating inflammatory responses and mitochondrial dysfunction. More importantly, Dio/siICAM-1@MSN@PDA-CD11b maintained favorable biosafety profiles in vivo. Therefore, Dio/siICAM-1@MSN@PDA-CD11b is expected to have clinical applications and provide a new avenue for the treatment of MI.
CRediT authorship contribution statement
Nannan Xu: Writing – review & editing, Resources, Project administration, Formal analysis, Conceptualization, Data curation, Visualization, Writing – original draft. Zuofei Chi: Writing – original draft, Software, Investigation, Formal analysis, Data curation. He Zhang: Supervision, Software, Data curation. Jiake Wu: Supervision, Software, Investigation, Data curation. Ruowen Sun: Writing – review & editing, Project administration, Investigation, Data curation. Chunyang Tian: Writing – original draft, Visualization, Methodology, Data curation, Conceptualization, Formal analysis, Investigation, Project administration, Resources, Writing – review & editing.
Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval
All animal experiments were approved by the Institutional Animal Care and Use Committee of YANGZHOU UNIVERSITY (Ethics No. 202406027).
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
Not applicable.
Contributor Information
Ruowen Sun, Email: sunrw@sj-hospital.org.
Chunyang Tian, Email: tianchunyang@sj-hospital.org.
Data availability
Data will be made available on request.
References
- 1.Shi H.T., Huang Z.H., Xu T.Z., Sun A.J., Ge J.B. New diagnostic and therapeutic strategies for myocardial infarction via nanomaterials. EBioMedicine. 2022;78 doi: 10.1016/j.ebiom.2022.103968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Salari N., Morddarvanjoghi F., Abdolmaleki A., Rasoulpoor S., Khaleghi A.A., Hezarkhani L.A., Shohaimi S., Mohammadi M. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc. Disord. 2023;23(1):206. doi: 10.1186/s12872-023-03231-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Liu T., Hao Y., Zhang Z., Zhou H., Peng S., Zhang D., Li K., Chen Y., Chen M. Advanced cardiac patches for the treatment of myocardial infarction. Circulation. 2024;149(25):2002–2020. doi: 10.1161/CIRCULATIONAHA.123.067097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Fanaroff A.C., Faggioni M. Managing myocardial infarction in the age of multimorbidity. J. Am. Coll. Cardiol. 2023;82(10):982–984. doi: 10.1016/j.jacc.2023.06.023. [DOI] [PubMed] [Google Scholar]
- 5.Jiang K., Hwa J., Xiang Y. Novel strategies for targeting neutrophil against myocardial infarction. Pharmacol. Res. 2024;205 doi: 10.1016/j.phrs.2024.107256. [DOI] [PubMed] [Google Scholar]
- 6.Daseke M.J., 2nd, Chalise U., Becirovic-Agic M., Salomon J.D., Cook L.M., Case A.J., Lindsey M.L. Neutrophil signaling during myocardial infarction wound repair. Cell. Signal. 2021;77 doi: 10.1016/j.cellsig.2020.109816. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zhang N., Aiyasiding X., Li W.J., Liao H.H., Tang Q.Z. Neutrophil degranulation and myocardial infarction. Cell Commun. Signal. : CCS. 2022;20(1):50. doi: 10.1186/s12964-022-00824-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Fu P., Han X., Lin Q.Y., Wang N., Sun F.F., Zhang Y.L., Li H.H., Zhang B. CD11b blockade ameliorates myocardial ischemia/reperfusion injury by reducing neutrophil and monocyte infiltration. J. Am. Heart Assoc. 2025;14(13) doi: 10.1161/JAHA.124.038142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Bandopadhyay S., Anand U., Gadekar V.S., Jha N.K., Gupta P.K., Behl T., Kumar M., Radha, Shekhawat M.S., Dey A. Dioscin: a review on pharmacological properties and therapeutic values. Biofactors. 2022;48(1):22–55. doi: 10.1002/biof.1815. [DOI] [PubMed] [Google Scholar]
- 10.Kong C., Lyu D., He C., Li R., Lu Q. Dioscin elevates lncRNA MANTIS in therapeutic angiogenesis for heart diseases. Aging Cell. 2021;20(7) doi: 10.1111/acel.13392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zhang Z., Zhao X., Gao M., Xu L., Qi Y., Wang J., Yin L. Dioscin alleviates myocardial infarction injury via regulating BMP4/NOX1-mediated oxidative stress and inflammation. Phytomedicine : Int. J. Phytother. Phytopharmacol. 2022;103 doi: 10.1016/j.phymed.2022.154222. [DOI] [PubMed] [Google Scholar]
- 12.Zhang S., Li L., Deng M., Wang Y., Shen A., Zhang L. Di'ao xinxuekang: therapeutic potential in cardiovascular diseases. Curr. Mol. Pharmacol. 2021;14(6):975–985. doi: 10.2174/1874467214666210203212341. [DOI] [PubMed] [Google Scholar]
- 13.Ran X., Yan Z., Yang Y., Hu G., Liu J., Hou S., Guo W., Kan X., Fu S. Dioscin improves pyroptosis in LPS-induced mice mastitis by activating AMPK/Nrf2 and inhibiting the NF-κB signaling pathway. Oxid. Med. Cell. Longev. 2020;2020 doi: 10.1155/2020/8845521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cao Y.J., Xu Y., Liu B., Zheng X., Wu J., Zhang Y., Li X.S., Qi Y., Sun Y.M., Wen W.B., Hou L., Wan C.P. Dioscin, a steroidal saponin isolated from Dioscorea nipponica, attenuates collagen-induced arthritis by inhibiting Th17 cell response. Am. J. Chin. Med. 2019;47(2):423–437. doi: 10.1142/S0192415X19500216. [DOI] [PubMed] [Google Scholar]
- 15.Benson V., McMahon A.C., Lowe H.C. ICAM-1 in acute myocardial infarction: a potential therapeutic target. Curr. Mol. Med. 2007;7(2):219–227. doi: 10.2174/156652407780059131. [DOI] [PubMed] [Google Scholar]
- 16.Lyck R., Enzmann G. The physiological roles of ICAM-1 and ICAM-2 in neutrophil migration into tissues. Curr. Opin. Hematol. 2015;22(1):53–59. doi: 10.1097/MOH.0000000000000103. [DOI] [PubMed] [Google Scholar]
- 17.Iqbal M.P., Azam I., Yousuf F.A., Kazmi K. Relationship of adhesion molecules (ICAM-1 and E-selectin) with ABO blood groups in patients hospitalized with acute myocardial infarction. Pakistan J. Med. Sci. 2024;40(7):1551–1555. doi: 10.12669/pjms.40.7.8978. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Aminian B., Abdi Ardekani A.R., Arandi N. ICAM-1 polymorphisms (G241R, K469E), in coronary artery disease and myocardial infarction. Iran J. Immounol. : IJI. 2007;4(4):227–235. doi: 10.22034/iji.2007.17202. [DOI] [PubMed] [Google Scholar]
- 19.Hu P., Dai T., Yu W., Luo Y., Huang S. Intercellular adhesion molecule 1 rs5498 polymorphism is associated with the risk of myocardial infarction. Oncotarget. 2017;8(32):52594–52603. doi: 10.18632/oncotarget.17529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Lino D.O.C., Freitas I.A., Meneses G.C., Martins A.M.C., Daher E.F., Rocha J.H.C., Silva Junior G.B. Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure. Braz. J. Med. Biol. Res. 2019;52(12) doi: 10.1590/1414-431X20198658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ode Y., Aziz M., Wang P. CIRP increases ICAM-1(+) phenotype of neutrophils exhibiting elevated iNOS and NETs in sepsis. J. Leukoc. Biol. 2018;103(4):693–707. doi: 10.1002/JLB.3A0817-327RR. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Buffone A., Jr., Anderson N.R., Hammer D.A. Human neutrophils will crawl upstream on ICAM-1 if Mac-1 is blocked. Biophys. J. 2019;117(8):1393–1404. doi: 10.1016/j.bpj.2019.08.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Oh J.Y., Yang G., Choi E., Ryu J.H. Mesoporous silica nanoparticle-supported nanocarriers with enhanced drug loading, encapsulation stability, and targeting efficiency. Biomater. Sci. 2022;10(6):1448–1455. doi: 10.1039/d2bm00010e. [DOI] [PubMed] [Google Scholar]
- 24.Tang F., Li L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 2012;24(12):1504–1534. doi: 10.1002/adma.201104763. [DOI] [PubMed] [Google Scholar]
- 25.Escriche-Navarro B., Escudero A., Lucena-Sánchez E., Sancenón F., García-Fernández A., Martínez-Máñez R. Mesoporous silica materials as an emerging tool for cancer immunotherapy. Adv. Sci. 2022;9(26) doi: 10.1002/advs.202200756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Nguyen T.L., Choi Y., Kim J. Mesoporous silica as a versatile platform for cancer immunotherapy. Adv. Mater. 2019;31(34) doi: 10.1002/adma.201803953. [DOI] [PubMed] [Google Scholar]
- 27.Croissant J.G., Fatieiev Y., Almalik A., Khashab N.M. Mesoporous silica and organosilica nanoparticles: physical chemistry, biosafety, delivery strategies, and biomedical applications. Adv. Healthcare Mater. 2018;7(4) doi: 10.1002/adhm.201700831. [DOI] [PubMed] [Google Scholar]
- 28.Kuang Y., Zhai J., Xiao Q., Zhao S., Li C. Polysaccharide/Mesoporous silica nanoparticle-based drug delivery systems: a review. Int. J. Biol. Macromol. 2021;193(Pt A):457–473. doi: 10.1016/j.ijbiomac.2021.10.142. [DOI] [PubMed] [Google Scholar]
- 29.Xu B., Li S., Shi R., Liu H. Multifunctional mesoporous silica nanoparticles for biomedical applications. Signal Transduct. Targeted Ther. 2023;8(1):435. doi: 10.1038/s41392-023-01654-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zhang W.J., Li S., Vijayan V., Lee J.S., Park S.S., Cui X., Chung I., Lee J., Ahn S.K., Kim J.R., Park I.K., Ha C.S. ROS- and pH-Responsive polydopamine functionalized Ti(3)C(2)T(x) MXene-Based nanoparticles as drug delivery nanocarriers with high antibacterial activity. Nanomaterials. 2022;12(24) doi: 10.3390/nano12244392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Yan M., Zhu L., Wu S., Cao Y., Mou N., Chi Q., Wang G., Zhong Y., Wu W. ROS responsive polydopamine nanoparticles to relieve oxidative stress and inflammation for ameliorating acute inflammatory bowel. Biomater. Adv. 2022;142 doi: 10.1016/j.bioadv.2022.213126. [DOI] [PubMed] [Google Scholar]
- 32.Zhang L., Bei Z., Li T., Qian Z. An injectable conductive hydrogel with dual responsive release of rosmarinic acid improves cardiac function and promotes repair after myocardial infarction. Bioact. Mater. 2023;29:132–150. doi: 10.1016/j.bioactmat.2023.07.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Park D.W., Jiang S., Liu Y., Siegal G.P., Inoki K., Abraham E., Zmijewski J.W. GSK3β-dependent inhibition of AMPK potentiates activation of neutrophils and macrophages and enhances severity of acute lung injury, American journal of physiology. Lung Cell. Mole. Physiol. 2014;307(10):L735–L745. doi: 10.1152/ajplung.00165.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hu D., Li R., Li Y., Wang M., Wang L., Wang S., Cheng H., Zhang Q., Fu C., Qian Z., Wei Q. Inflammation-targeted nanomedicines alleviate oxidative stress and reprogram macrophages polarization for myocardial infarction treatment. Adv. Sci. 2024;11(21) doi: 10.1002/advs.202308910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Liu Y., Wang S., Zhang J., Sun Q., Xiao Y., Chen J., Yao M., Zhang G., Huang Q., Zhao T., Huang Q., Shi X., Feng C., Ai K., Bai Y. Reprogramming the myocardial infarction microenvironment with melanin-based composite nanomedicines in mice. Nat. Commun. 2024;15(1):6651. doi: 10.1038/s41467-024-50854-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Zheng G., Zhao R., Xu A., Shen Z., Chen X., Shao J. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. Eur. J. Pharmaceut. Sci. : Off. J. Eur. Fed. Pharma. Sci. 2018;111:492–502. doi: 10.1016/j.ejps.2017.10.036. [DOI] [PubMed] [Google Scholar]
- 37.Shen Z., Wen H., Zhou H., Hao L., Chen H., Zhou X. Coordination bonding-based polydopamine-modified mesoporous silica for sustained avermectin release, materials science & engineering. Mater. Biol. Appl. 2019;105 doi: 10.1016/j.msec.2019.110073. [DOI] [PubMed] [Google Scholar]
- 38.Li H., Zhu J., Xu Y.W., Mou F.F., Shan X.L., Wang Q.L., Liu B.N., Ning K., Liu J.J., Wang Y.C., Mi J.X., Wei X., Shao S.J., Cui G.H., Lu R., Guo H.D. Notoginsenoside R1-loaded mesoporous silica nanoparticles targeting the site of injury through inflammatory cells improves heart repair after myocardial infarction. Redox Biol. 2022;54 doi: 10.1016/j.redox.2022.102384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Yang L., Han Y., Jaffré F., Nilsson-Payant B.E., Bram Y., Wang P., Zhu J., Zhang T., Redmond D., Houghton S., Uhl S., Borczuk A., Huang Y., Richardson C., Chandar V., Acklin J.A., Lim J.K., Chen Z., Xiang J., Ho D.D., tenOever B.R., Schwartz R.E., Evans T., Chen S. An immuno-cardiac model for macrophage-mediated inflammation in COVID-19 hearts. Circ. Res. 2021;129(1):33–46. doi: 10.1161/CIRCRESAHA.121.319060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Zhang P., Xu Q., Li X., Wang Y. pH-responsive polydopamine nanoparticles for photothermally promoted gene delivery, materials science & engineering. Mater. Biol. Appl. 2020;108 doi: 10.1016/j.msec.2019.110396. [DOI] [PubMed] [Google Scholar]
- 41.Mhatre O., Reddy B.P.K., Patnaik C., Chakrabarty S., Ingle A., De A., Srivastava R. pH-responsive delivery of anti-metastatic niclosamide using mussel inspired polydopamine nanoparticles. Int. J. Pharm. 2021;597 doi: 10.1016/j.ijpharm.2021.120278. [DOI] [PubMed] [Google Scholar]
- 42.Khan S.Q., Khan I., Gupta V. CD11b activity modulates pathogenesis of lupus nephritis. Front. Med. 2018;5:52. doi: 10.3389/fmed.2018.00052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Bouti P., Klein B., Verkuijlen P.J.H., Schornagel K., van Alphen F.P.J., Taris K.H., van den Biggelaar M., Hoogendijk A.J., van Bruggen R., Kuijpers T.W., Matlung H.L. SKAP2 acts downstream of CD11b/CD18 and regulates neutrophil effector function. Front. Immunol. 2024;15 doi: 10.3389/fimmu.2024.1344761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Heo J.S. Neutrophil CD11b as a promising marker for early detection of neonatal sepsis. Clin. Exp. Ped. 2021;64(1):28–30. doi: 10.3345/cep.2020.00626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Dogaru G., Bulboaca A., Boarescu P.M., Ciumarnean L., Rus V., Sitar-Taut A.V., Munteanu C., Bodisz G., Stanescu I. The effect of mofettes on oxidative stress/antioxidant balance in experimental myocardial ischemia. In Vivo (Attiki) 2019;33(6):1911–1920. doi: 10.21873/invivo.11685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Neri M., Fineschi V., Di Paolo M., Pomara C., Riezzo I., Turillazzi E., Cerretani D. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr. Vasc. Pharmacol. 2015;13(1):26–36. doi: 10.2174/15701611113119990003. [DOI] [PubMed] [Google Scholar]
- 47.Bai B., Yang Y., Wang Q., Li M., Tian C., Liu Y., Aung L.H.H., Li P.F., Yu T., Chu X.M. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020;11(9):776. doi: 10.1038/s41419-020-02985-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Zheng L., Han X., Hu Y., Zhao X., Yin L., Xu L., Qi Y., Xu Y., Han X., Liu K., Peng J. Dioscin ameliorates intestinal ischemia/reperfusion injury via adjusting miR-351-5p/MAPK13-mediated inflammation and apoptosis. Pharmacol. Res. 2019;139:431–439. doi: 10.1016/j.phrs.2018.11.040. [DOI] [PubMed] [Google Scholar]
- 49.Dong L., Yin L., Li R., Xu L., Xu Y., Han X., Qi Y. Dioscin alleviates lung ischemia/reperfusion injury by regulating FXR-Mediated oxidative stress, apoptosis, and inflammation. Eur. J. Pharmacol. 2021;908 doi: 10.1016/j.ejphar.2021.174321. [DOI] [PubMed] [Google Scholar]
- 50.Yang B., Xu B., Zhao H., Wang Y.B., Zhang J., Li C.W., Wu Q., Cao Y.K., Li Y., Cao F. Dioscin protects against coronary heart disease by reducing oxidative stress and inflammation via Sirt1/Nrf2 and p38 MAPK pathways. Mol. Med. Rep. 2018;18(1):973–980. doi: 10.3892/mmr.2018.9024. [DOI] [PubMed] [Google Scholar]
- 51.Cheng J., Sun C., Zhang J., Zou Q., Hao Q., Xue Y. The protective effects of preconditioning with dioscin on myocardial Ischemia/reperfusion-induced ventricular arrhythmias by increasing connexin 43 expression in rats. J. Cardiovasc. Pharmacol. Therapeut. 2019;24(3):262–268. doi: 10.1177/1074248418801567. [DOI] [PubMed] [Google Scholar]
- 52.Ramachandra C.J.A., Hernandez-Resendiz S., Crespo-Avilan G.E., Lin Y.H., Hausenloy D.J. Mitochondria in acute myocardial infarction and cardioprotection. EBioMedicine. 2020;57 doi: 10.1016/j.ebiom.2020.102884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Zhou M., Yu Y., Luo X., Wang J., Lan X., Liu P., Feng Y., Jian W. Myocardial ischemia-reperfusion injury: therapeutics from a mitochondria-centric perspective. Cardiology. 2021;146(6):781–792. doi: 10.1159/000518879. [DOI] [PubMed] [Google Scholar]
- 54.Shen T., Lyu D., Zhang M., Shang H., Lu Q. Dioscin alleviates cardiac dysfunction in acute myocardial infarction via rescuing mitochondrial malfunction. Front. Cardiovasc. Med. 2022;9 doi: 10.3389/fcvm.2022.783426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Yu J., Liu Y., Peng W., Xu Z. Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients. J. Clin. Lab. Anal. 2022;36(10) doi: 10.1002/jcla.24685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Wu S., Xu H., Peng J., Wang C., Jin Y., Liu K., Sun H., Qin J. Potent anti-inflammatory effect of dioscin mediated by suppression of TNF-α-induced VCAM-1, ICAM-1and EL expression via the NF-κB pathway. Biochimie. 2015;110:62–72. doi: 10.1016/j.biochi.2014.12.022. [DOI] [PubMed] [Google Scholar]
- 57.Zheng L., Yin L., Xu L., Qi Y., Li H., Xu Y., Han X., Liu K., Peng J. Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/AMPK signaling pathway in vivo. Biomed. Pharma. Biomed. Pharmacother. 2018;97:481–488. doi: 10.1016/j.biopha.2017.10.153. [DOI] [PubMed] [Google Scholar]
- 58.Morsing S.K.H., Rademakers T., Brouns S.L.N., Stalborch A.D.V., Donners M., van Buul J.D. ADAM10-Mediated cleavage of ICAM-1 is involved in neutrophil transendothelial migration. Cells. 2021;10(2) doi: 10.3390/cells10020232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Zhang T., Sun Y., Xia J., Fan H., Shi D., Wu Q., Huang M., Hou X.Y. Targeting HPK1 inhibits neutrophil responses to mitigate post-stroke lung and cerebral injuries. EMBO Mol. Med. 2025;17(5):1018–1040. doi: 10.1038/s44321-025-00220-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Chen W., Liu L., Tang M., Li J., Yuan W., Yin D., Cao Y., Tian J. Type I collagen-targeted liposome delivery of Serca2a modulates myocardium calcium homeostasis and reduces cardiac fibrosis induced by myocardial infarction, materials today. Bio. 2024;28 doi: 10.1016/j.mtbio.2024.101162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Yang C., Fu J., Zheng F., Fu Y., Duan X., Zuo R., Zhu J. Aconitine promotes ROS-Activated P38/MAPK/Nrf2 pathway to inhibit autophagy and promote myocardial injury. J. Cardiothorac. Surg. 2024;19(1):665. doi: 10.1186/s13019-024-03149-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Zhang L., Meng W., Chen X., Ning Y., Sun M., Wang R. MiR-150-5p regulates the functions of type 2 innate lymphoid cells via the ICAM-1/p38 MAPK axis in allergic rhinitis. Mol. Cell. Biochem. 2022;477(4):1009–1022. doi: 10.1007/s11010-021-04346-4. [DOI] [PubMed] [Google Scholar]
- 63.Zhang C., Zhang Q., Qin L., Yan Z., Wu L., Liu T. Dioscin ameliorates experimental autoimmune thyroiditis via the mTOR and TLR4/NF-κB signaling. Drug Des. Dev. Ther. 2023;17:2273–2285. doi: 10.2147/DDDT.S410901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Bai J., Zhang X., Meng W., Xu H., Liu Y., Zhong Y., Lin X., Wang J., Fan D., Lv G., Gu Y. Dioscin decreases M2 polarization via inhibiting a positive feedback loop between RBM47 and NF-κB in glioma. Phytomedicine : Int. J. Phytother. Phytopharmacol. 2024;128 doi: 10.1016/j.phymed.2024.155417. [DOI] [PubMed] [Google Scholar]
- 65.Cui L., Yang G., Ye J., Yao Y., Lu G., Chen J., Fang L., Lu S., Zhou J. Dioscin elicits anti-tumour immunity by inhibiting macrophage M2 polarization via JNK and STAT3 pathways in lung cancer. J. Cell Mol. Med. 2020;24(16):9217–9230. doi: 10.1111/jcmm.15563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Tao X., Sun X., Yin L., Han X., Xu L., Qi Y., Xu Y., Li H., Lin Y., Liu K., Peng J. Dioscin ameliorates cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via HMGB-1 inhibition. Free Radic. Biol. Med. 2015;84:103–115. doi: 10.1016/j.freeradbiomed.2015.03.003. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Data will be made available on request.









